GlassScriptPhysician profile
David Brian Wiltfong
NPI 1467475731
$12,666.51
in general payments reported to CMS, 2019-2025
49 companies · $6,667 in 2025
The $6,667 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $514 · 2021: $912 · 2022: $1,111 · 2023: $885 · 2024: $1,588 · 2025: $6,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $5,639 · Food and Beverage: $2,978 · Education: $267 · Travel and Lodging: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $5,638.89 |
| Food and Beverage | $2,977.99 |
| Education | $266.98 |
| Travel and Lodging | $256.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $5,638.89 | 2025 | Nanoknife |
| Procept Biorobotics Corporation | $836.43 | 2022-2024 | Aquabeam System, Aquabeam Robotic System |
| Janssen Biotech, INC. | $633.98 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Sumitomo Pharma America, INC. | $633.83 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $623.02 | 2019-2023 | Veozah |
| Abbvie INC. | $405.82 | 2019-2025 | Botox |
| Boston Scientific Corporation | $383.67 | 2019-2025 | Spaceoar Vue System - 10ml, Lithovue |
| Isoray, INC | $339.68 | 2020-2024 | Brachytherapy Source |
| Teleflex LLC | $255.49 | 2021-2025 | Urolift, Barrigel |
| Myovant Sciences INC. | $253.02 | 2021-2022 | |
| Urogen Pharma, INC. | $249.02 | 2021-2025 | Jelmyto |
| Pfizer INC. | $237.09 | 2019-2025 | |
| Telix Pharmaceuticals | $173.39 | 2024 | Illuccix |
| Neotract INC. | $172.56 | 2019 | |
| Dendreon Pharmaceuticals LLC | $172.34 | 2021-2025 | Provenge |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wiltfong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.